Shares of Omeros Rocket Higher (43%), Wedbush's Moussatos Says OMS302 Could Benefit from FDA Restrictions on Topical Solutions in Intraocular Lens Replacement Surgery, Boosted Target from $18 to $28, Outperform Maintained